| 引用本文:苏庆珠1，王耀霞2，杨威1.养心氏片治疗肺源性心脏病的临床疗效观察[J].世界中医药,2016,(07):. |
|
| 养心氏片治疗肺源性心脏病的临床疗效观察 |
| Clinical Effect Observation of Yangxinshi Tablet in the Treatment of Pulmonary Heart Disease |
| 投稿时间：2016-06-10 |
| DOI：10.3969/j.issn.1673-7202.2016.07.021 |
| 中文关键词: 养心氏片 肺源性心脏病 心力衰竭 左心室射血分数 |
| English Keywords:Yangxinshi tablet Pulmonary heart disease Heart failure LVEF |
| 基金项目: |
|
| 摘要点击次数: 1186 |
| 全文下载次数: 1103 |
| 中文摘要: |
| 目的：评价养心氏片治疗肺源性心脏病的临床疗效。方法：将60例肺源性心脏病患者随机分为对照组和养心氏组，每组30例，30 d疗程后，比较2组患者的临床症状、LVEF、心脏等容舒张时间、hs-CRP、NT-proBNP、血脂、血压和不良反应。结果：治疗后，1）养心氏组临床症状改善总有效率（90.0%），高于对照组（66.7%），差异有统计学意义（P<0.05）；2）养心氏组LVEF(55±3.3)%，高于对照组(50±2.4%)（P<0.05）；3）养心氏组hs-CRP(1.09±0.22)mg/L，低于对照组(1.34±0.31)mg/L（P<0.05）；4）养心氏组NT-proBNP(641±145)ng/L，低于对照组(923±122)ng/L（P<0.05）；5）养心氏组血脂水平优于对照组；6）养心氏组血压(125±9.6/85±3.4)mmHg，低于对照组(130±6.6/83±7.5)mmHg（P >0.05）；7）养心氏组不良反应发生率（6.7%），低于对照组（16.7%）（P<0.05）。结论：养心氏片治疗肺源性心脏病能够显著改善临床症和血脂；提高LVEF，降低hs-CRP、NT-proBNP和不良反应，安全性高，具有临床指导意义。 |
| English Summary: |
| To evaluate the effects of Yangxinshi tablet on heart failure of pulmonary heart disease. Methods: Sixty patients with pulmonary heart disease in the hospital were randomly divided into control group and Yangxinshi group, with 30 cases in each group. After 30 days treatment, the clinical symptoms, LVEF, hs-CRP, NT-proBNP, blood lipid level, blood pressure and adverse reactions of all patients were detected. Results: After treatment, 1) the total effective rate of improving clinical symptom in Yangxinshi group (90.0%) was significantly higher than that of the control group (66.7%), and the difference was statistically significant (P<0.05); 2) LVEF in Yangxinshi group (55±3.3)% was significantly higher than that of in control group (50±2.4)%, and the difference was statistically significant (P<0.05); 3) the hs-CRP in Yangxinshi group (1.09±0.22) mg/L was significantly lower than that of the control group (1.34±0.31) mg/L and the difference was statistically significant (P<0.05); 4) the NT-proBNP in Yangxinshi group (641±145) ng/L was significantly lower than that of the control group (923±122) ng/L (P<0.05); 5) the blood lipid level in Yangxinshi group (P<0.05); 6) the blood pressure in Yangxinshi group (125±9.6/85±3.4)mmHg was lower than that of the control group (130±6.6/83±7.5) mmHg, but the difference was not statistically significant (P>0.05); 7) the incidence of adverse reactions in Yangxinshi group (6.7%) was significantly lower than that of the control group (16.7%) (P<0.05). Conclusion: Yangxinshi tablet on heart failure of pulmonary heart disease can significantly improve clinical symptom and blood lipid level, enhance LVEF, reduce hs-CRP, NT-proBNP and incidence of adverse reactions, which has high safety and a guiding significance for clinic. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
